ADAP

Adaptimmune Therapeutics

0.3050 USD
+0.0550
22.00%
At close Apr 2, 4:00 PM EDT
After hours
0.2941
-0.0109
3.57%
1 day
22.00%
5 days
27.08%
1 month
-40.28%
3 months
-51.08%
6 months
-65.13%
Year to date
-51.08%
1 year
-78.21%
5 years
-89.37%
10 years
-98.09%
 

About: Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.

Employees: 506

0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

167% more call options, than puts

Call options by funds: $24K | Put options by funds: $9K

7% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 14

1.85% less ownership

Funds ownership: 9.95% [Q3] → 8.1% (-1.85%) [Q4]

3% less funds holding

Funds holding: 80 [Q3] → 78 (-2) [Q4]

14% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 21

50% less funds holding in top 10

Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]

54% less capital invested

Capital invested by funds: $145M [Q3] → $67M (-$78.1M) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$1.40
359%
upside
Avg. target
$1.91
527%
upside
High target
$3
884%
upside

4 analyst ratings

positive
75%
neutral
25%
negative
0%
HC Wainwright & Co.
Arthur He
14% 1-year accuracy
3 / 22 met price target
884%upside
$3
Buy
Maintained
1 Apr 2025
Guggenheim
Michael Schmidt
7% 1-year accuracy
1 / 14 met price target
474%upside
$1.75
Buy
Maintained
26 Mar 2025
Wells Fargo
Yanan Zhu
11% 1-year accuracy
1 / 9 met price target
392%upside
$1.50
Equal-Weight
Maintained
21 Mar 2025
Scotiabank
George Farmer
0% 1-year accuracy
0 / 1 met price target
359%upside
$1.40
Sector Outperform
Maintained
21 Mar 2025

Financial journalist opinion

Based on 3 articles about ADAP published over the past 30 days

Neutral
Seeking Alpha
1 week ago
Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q4 2024 Earnings Conference Call March 20, 2025 8:00 AM ET Company Participants Juli Miller - IR Adrian Rawcliffe - CEO Cintia Piccina - Chief Commercial Officer Gavin Wood - CFO Dennis Williams - SVP, Late Stage Development John Lunger - VP, Manufacturing and Supply Chain Conference Call Participants Jonathan Chang - Leerink Partners Tony Butler - Rodman & Renshaw Graig Suvannavejh - Mizuho George Farmer - Scotiabank Arthur He - H.C. Wainwright Michael Kim - Zacks Small Cap Research Peter Lawson - Barclays Operator Hello, and welcome to the Adaptimmune's Q4 and Full Year 2024 Business Update Conference Call.
Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript
Neutral
Newsfile Corp
1 week ago
Adaptimmune Provides Q4 and Full Year 2024 Business Update
TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achieved Lete-cel on track to initiate rolling BLA submission late 2025; approval anticipated 2026 Corporate restructure completed in February 2025 and implementing additional cost reduction for PRAME and CD70 programs At the end of 2024, Adaptimmune had Total Liquidity 1 of $152 million Evaluating all strategic options to maximize shareholder value Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today provided a Q4 and Full Year 2024 business update. Adrian Rawcliffe, Adaptimmune's Chief Executive Officer: "2025 is the year of commercial execution for Tecelra, as we begin to generate value from our promising sarcoma franchise.
Adaptimmune Provides Q4 and Full Year 2024 Business Update
Neutral
Newsfile Corp
3 weeks ago
Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2024, before the US markets open on Thursday, March 20, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m.
Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025
Neutral
Newsfile Corp
2 months ago
Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that management will participate in the Guggenheim Securities SMID Cap Biotech Conference this February. Guggenheim Securities SMID Cap Biotech Conference, New York, NY Fireside chat with Adrian Rawcliffe, CEO: February 6 at 3:00 p.m.
Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025
Neutral
Newsfile Corp
2 months ago
Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
The Company will present at the Annual J.P. Morgan Healthcare Conference, providing business updates on its sarcoma franchise and other cell therapy pipeline assets Adaptimmune Allo-T program to be featured at the Biotech ShowCase (TM) and the Wuxi Global Forum 2025 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 13, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that letetresgene autoleucel (lete-cel), has been granted breakthrough therapy designation by the U.S. FDA for the treatment of patients with unresectable or metastatic myxoid/round cell liposarcoma (MRCLS) who have received prior anthracycline-based chemotherapy, are positive for HLA-A*02:01, HLA-A*02:05, or HLA-A*02:06, and whose tumor expresses the NY-ESO-1 antigen.
Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
Neutral
Newsfile Corp
3 months ago
Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK
Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31, 2025 Gavin Wood, Chief Financial Officer, will step down from the Company May 31, 2025 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 19, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that two of its executive leadership team members based in the UK will leave the Company next year.
Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK
Neutral
Newsfile Corp
3 months ago
First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)
Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcoma Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 2, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that the first patient has been treated with TECELRA® (afamitresgene autoleucel). TECELRA is the first engineered cell therapy for a solid tumor cancer approved in the U.S., and the first new therapy option in more than a decade for synovial sarcoma, a rare, soft tissue cancer that most commonly impacts young adults.
First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)
Neutral
Seeking Alpha
4 months ago
Adaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call Transcript
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Dan Od-Cohen - IR Adrian Rawcliffe - CEO Gavin Wood - CFO Dennis Williams - SVP, Late Stage Development Conference Call Participants Marc Frahm - TD Cowen Tony Butler - Rodman & Renshaw Paul Jeng - Guggenheim Yen-Der Li - Leerink Partners Graig Suvannavejh - Mizuho Securities Arthur He - H.C. Wainwright George Farmer - Scotiabank Michael Kim - Zacks Small Cap Research Peter Lawson - Barclays Operator Hello and welcome to the Adaptimmune Therapeutics Third Quarter 2024 Results Conference Call.
Adaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call Transcript
Neutral
Newsfile Corp
4 months ago
Adaptimmune Reports Q3 2024 Financial and Business Updates
Tecelra® launch on track with 9 Authorized Treatment Centers available to initiate patient treatment journey, and the first patient apheresed in Q3; expect first commercial revenues in Q4 and the number of treated patients to accelerate throughout 2025 Lete-cel IGNYTE-ESO pivotal trial primary analysis reports 42% overall response rate in synovial sarcoma and myxoid/round cell liposarcoma (MRCLS); full data at CTOS conference on November 16 Company restructuring to prioritize commercial sarcoma franchise and R&D programs with highest potential return on invested capital and transformational benefit to patients Planned 33% reduction in headcount in Q1, 2025 as part of approximately $300 million in aggregate cost savings over the next four years enables company to target an operating breakeven during 2027 At the end of Q3, Adaptimmune had Total Liquidity1 of $186.1 million Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 13, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today reports financial results and business updates for the third quarter ended September 30, 2024. The Company will host a live webcast at 4:30 p.m.
Adaptimmune Reports Q3 2024 Financial and Business Updates
Neutral
Newsfile Corp
4 months ago
Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial
42% of people with advanced or metastatic synovial sarcoma or MRCLS had clinical responses with lete-cel Results include six complete responses (6/64); twenty-one partial responses (21/64) Data to be presented at Connective Tissue Oncology Society 2024 Annual Meeting Company plans to initiate a rolling BLA submission for lete-cel for the treatment of advanced or metastatic synovial sarcoma and MRCLS by end of 2025 Company to host virtual KOL event Monday, November 18, 2024; 2:30 PM EST featuring Dr. Sandra D'Angelo, M.D. (Memorial Sloan Kettering Cancer Center) - register here Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 13, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced data from the primary analysis of its pivotal Phase 2 IGNYTE-ESO trial of lete-cel in people with synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) who received previous anthracycline-based therapy.
Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial
Charts implemented using Lightweight Charts™